Protalix Biotherapeutics, Inc. (PLX) Stock Price & Analysis
Protalix Biotherapeutics, Inc. (PLX) rose 1.02% to USD 1.98 as of June 10, 2026 at 04:36 UTC, according to Nexqual real-time market data.
PLX last closed at USD 1.96; the session ranged USD 1.96–2.03 on volume of 460,291 shares. Market capitalization is $159.53M, with a 52-week range of USD 1.32–3.19 (ASE). Source: Nexqual, June 10, 2026 at 04:36 UTC.
Key Statistics (as of June 10, 2026 at 04:36 UTC)
| Price | USD 1.98 |
|---|---|
| Change | ▲ 1.02% (up) |
| Previous Close | USD 1.96 |
| Open | USD 1.96 |
| Day Range | USD 1.96 – 2.03 |
| 52-Week Range | USD 1.32 – 3.19 |
| Volume | 460,291 shares |
| Market Cap | $159.53M |
| Exchange | ASE |
Technical Analysis (PLX)
Nexqual's technical model rates PLX "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:36 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.02 (neutral) |
| vs SMA50 | Below (USD 2.11) |
| MACD | -0.03 (negative) |
Analyst Ratings (PLX)
Wall Street analysts rate PLX "Strong Buy" based on 2 analysts, with a mean price target of USD 11 (range USD 10–12), per Nexqual as of June 10, 2026 at 04:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 11 |
| High Target | USD 12 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (PLX)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $12.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.22 vs est -0.01 ▲ beat |
| 2025-12-31 | USD -0.07 vs est 0.01 ▼ miss |
| 2025-09-30 | USD 0.03 vs est 0.06 ▼ miss |
| 2025-06-30 | USD 0 vs est 0.03 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Financials & Fundamentals (PLX)
| Total Revenue | $76.38M |
|---|---|
| Revenue Growth (YoY) | +233.70% |
| Gross Margin | +45.24% |
| Operating Margin | +62.65% |
| Profit Margin | +20.07% |
| ROE | +27.27% |
| Debt / Equity | 12.62 |
| Current Ratio | 3.15 |
| Total Cash | $51.08M |
| Total Debt | $8.48M |
| Free Cash Flow | $6.78M |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Financial Health Score (PLX)
Nexqual rates Protalix Biotherapeutics, Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 04:36 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 45% |
| Balance Sheet | Strong — $51M cash vs $8M debt, net cash position |
| Cash Flow | Solid — FCF $7M, 13% margin |
| Efficiency | Strong — ROE 27%, ROA 14.0% |
Ownership (PLX)
| Insider Ownership | +3.88% |
|---|---|
| Institutional Ownership | +21.30% |
| Shares Outstanding | 80.57M |
| Float | 72.73M |
| Short % of Float | +5.08% |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
Leadership (PLX)
Protalix Biotherapeutics, Inc. is led by Dror Bashan (age 58), President, CEO & Director, per Nexqual as of June 10, 2026 at 04:36 UTC.
| President, CEO & Director | Dror Bashan (age 58) |
|---|---|
| Senior VP, CFO Treasurer & Secretary | Gilad Mamlok (age 57) |
| SVP & COO | Yaron Naos B.Sc. (age 61) |
| Vice President of Human Resources | Yael Fellous |
Major Backers & Investors (PLX)
Notable institutional backers of Protalix Biotherapeutics, Inc. include MAK Capital One LLC, Renaissance Technologies, Fidelity, according to Nexqual as of June 10, 2026 at 04:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAK Capital One LLC | 4.4% |
| Renaissance Technologies | 1.52% |
| Fidelity | 0.88% |
| Stratos Wealth Partners, Ltd. | 0.62% |
| Prospera Financial Services Inc. | 0.52% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.48% |
| State Street | 1.21% |
| Northern Trust | 1.1% |
| Geode Capital | 1.07% |
| Vanguard Group | 0.98% |
Source: Nexqual, June 10, 2026 at 04:36 UTC.
From Protalix Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
- The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
- It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
- The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.
Partnerships
- Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BLRX | BioLineRx Ltd. | USD 3.21 | ▼ 0.62% |
| PULM | Pulmatrix, Inc. | USD 1.38 | ▲ 3.76% |
| CANF | Can-Fite Biopharma Ltd | USD 2.91 | ▼ 5.83% |
| VSTM | Verastem, Inc. | USD 3.82 | ▲ 2.96% |
| RDHL | Redhill Biopharma Ltd. | USD 0.8 | ▼ 22.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:36 UTC. This page is informational and not investment advice.